Hmdb loader
You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:52 UTC
Update Date2022-03-07 02:51:58 UTC
HMDB IDHMDB0015399
Secondary Accession Numbers
  • HMDB15399
Metabolite Identification
Common NameArformoterol
DescriptionArformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. Arformoterol inhalation is used to prevent bronchoconstriction in people with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients using long acting beta agonists for the treatment of asthma.
Structure
Data?1582753292
Synonyms
ValueSource
(-)-FormoterolChEBI
(R,R)-FormoterolChEBI
3-Formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarateHMDB
OxisHMDB
Formoterol fumarateHMDB
BD 40aHMDB
ForadilHMDB
Formoterol, ((r*,r*)-(+-))-isomerHMDB
EformoterolHMDB
FormoterolHMDB
Formoterol fumarate, ((r*,r*)-(+-))-isomerHMDB
Chemical FormulaC19H24N2O4
Average Molecular Weight344.4049
Monoisotopic Molecular Weight344.173607266
IUPAC NameN-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide
Traditional Namearformoterol
CAS Registry Number67346-49-0
SMILES
COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1
InChI Identifier
InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1
InChI KeyBPZSYCZIITTYBL-YJYMSZOUSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenylpropane
  • Anilide
  • Phenoxy compound
  • Anisole
  • Phenol ether
  • N-arylamide
  • Methoxybenzene
  • Alkyl aryl ether
  • 1-hydroxy-2-unsubstituted benzenoid
  • Phenol
  • Aralkylamine
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Amino acid or derivatives
  • 1,2-aminoalcohol
  • Carboxamide group
  • Secondary amine
  • Carboxylic acid derivative
  • Secondary aliphatic amine
  • Ether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organooxygen compound
  • Organic oxygen compound
  • Carbonyl group
  • Alcohol
  • Organic nitrogen compound
  • Organopnictogen compound
  • Aromatic alcohol
  • Organic oxide
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
  • N-[2-hydroxy-5-(1-hydroxy-2-\{[1-(4-methoxyphenyl)propan-2-yl]amino\}ethyl)phenyl]formamide (CHEBI:408174 )
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water Solubility0.042 g/LNot Available
LogP2.2Not Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.042 g/LALOGPS
logP1.91ALOGPS
logP1.06ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)8.61ChemAxon
pKa (Strongest Basic)9.81ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area90.82 ŲChemAxon
Rotatable Bond Count8ChemAxon
Refractivity97.87 m³·mol⁻¹ChemAxon
Polarizability36.56 ųChemAxon
Number of Rings2ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+181.5831661259
DarkChem[M-H]-180.42631661259
DeepCCS[M+H]+188.18430932474
DeepCCS[M-H]-185.82630932474
DeepCCS[M-2H]-219.5630932474
DeepCCS[M+Na]+194.78830932474
AllCCS[M+H]+186.532859911
AllCCS[M+H-H2O]+183.632859911
AllCCS[M+NH4]+189.332859911
AllCCS[M+Na]+190.132859911
AllCCS[M-H]-184.232859911
AllCCS[M+Na-2H]-184.632859911
AllCCS[M+HCOO]-185.232859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
ArformoterolCOC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C14304.2Standard polar33892256
ArformoterolCOC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C13153.9Standard non polar33892256
ArformoterolCOC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C13346.7Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Arformoterol,1TMS,isomer #1COC1=CC=C(C[C@@H](C)NC[C@H](O[Si](C)(C)C)C2=CC=C(O)C(NC=O)=C2)C=C13238.9Semi standard non polar33892256
Arformoterol,1TMS,isomer #2COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC=C(O[Si](C)(C)C)C(NC=O)=C2)C=C13270.5Semi standard non polar33892256
Arformoterol,1TMS,isomer #3COC1=CC=C(C[C@@H](C)N(C[C@H](O)C2=CC=C(O)C(NC=O)=C2)[Si](C)(C)C)C=C13273.9Semi standard non polar33892256
Arformoterol,1TMS,isomer #4COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC=C(O)C(N(C=O)[Si](C)(C)C)=C2)C=C13021.6Semi standard non polar33892256
Arformoterol,2TMS,isomer #1COC1=CC=C(C[C@@H](C)NC[C@H](O[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C(NC=O)=C2)C=C13194.4Semi standard non polar33892256
Arformoterol,2TMS,isomer #2COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C)C2=CC=C(O)C(NC=O)=C2)[Si](C)(C)C)C=C13213.8Semi standard non polar33892256
Arformoterol,2TMS,isomer #3COC1=CC=C(C[C@@H](C)NC[C@H](O[Si](C)(C)C)C2=CC=C(O)C(N(C=O)[Si](C)(C)C)=C2)C=C12920.9Semi standard non polar33892256
Arformoterol,2TMS,isomer #4COC1=CC=C(C[C@@H](C)N(C[C@H](O)C2=CC=C(O[Si](C)(C)C)C(NC=O)=C2)[Si](C)(C)C)C=C13264.5Semi standard non polar33892256
Arformoterol,2TMS,isomer #5COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC=C(O[Si](C)(C)C)C(N(C=O)[Si](C)(C)C)=C2)C=C13038.4Semi standard non polar33892256
Arformoterol,2TMS,isomer #6COC1=CC=C(C[C@@H](C)N(C[C@H](O)C2=CC=C(O)C(N(C=O)[Si](C)(C)C)=C2)[Si](C)(C)C)C=C13013.4Semi standard non polar33892256
Arformoterol,3TMS,isomer #1COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C(NC=O)=C2)[Si](C)(C)C)C=C13246.8Semi standard non polar33892256
Arformoterol,3TMS,isomer #1COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C(NC=O)=C2)[Si](C)(C)C)C=C12891.4Standard non polar33892256
Arformoterol,3TMS,isomer #1COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C(NC=O)=C2)[Si](C)(C)C)C=C13639.8Standard polar33892256
Arformoterol,3TMS,isomer #2COC1=CC=C(C[C@@H](C)NC[C@H](O[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C(N(C=O)[Si](C)(C)C)=C2)C=C12978.4Semi standard non polar33892256
Arformoterol,3TMS,isomer #2COC1=CC=C(C[C@@H](C)NC[C@H](O[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C(N(C=O)[Si](C)(C)C)=C2)C=C12660.7Standard non polar33892256
Arformoterol,3TMS,isomer #2COC1=CC=C(C[C@@H](C)NC[C@H](O[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C(N(C=O)[Si](C)(C)C)=C2)C=C13452.6Standard polar33892256
Arformoterol,3TMS,isomer #3COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C)C2=CC=C(O)C(N(C=O)[Si](C)(C)C)=C2)[Si](C)(C)C)C=C13002.4Semi standard non polar33892256
Arformoterol,3TMS,isomer #3COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C)C2=CC=C(O)C(N(C=O)[Si](C)(C)C)=C2)[Si](C)(C)C)C=C12814.0Standard non polar33892256
Arformoterol,3TMS,isomer #3COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C)C2=CC=C(O)C(N(C=O)[Si](C)(C)C)=C2)[Si](C)(C)C)C=C13615.3Standard polar33892256
Arformoterol,3TMS,isomer #4COC1=CC=C(C[C@@H](C)N(C[C@H](O)C2=CC=C(O[Si](C)(C)C)C(N(C=O)[Si](C)(C)C)=C2)[Si](C)(C)C)C=C13050.6Semi standard non polar33892256
Arformoterol,3TMS,isomer #4COC1=CC=C(C[C@@H](C)N(C[C@H](O)C2=CC=C(O[Si](C)(C)C)C(N(C=O)[Si](C)(C)C)=C2)[Si](C)(C)C)C=C12878.4Standard non polar33892256
Arformoterol,3TMS,isomer #4COC1=CC=C(C[C@@H](C)N(C[C@H](O)C2=CC=C(O[Si](C)(C)C)C(N(C=O)[Si](C)(C)C)=C2)[Si](C)(C)C)C=C13654.3Standard polar33892256
Arformoterol,4TMS,isomer #1COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C(N(C=O)[Si](C)(C)C)=C2)[Si](C)(C)C)C=C13085.9Semi standard non polar33892256
Arformoterol,4TMS,isomer #1COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C(N(C=O)[Si](C)(C)C)=C2)[Si](C)(C)C)C=C12735.0Standard non polar33892256
Arformoterol,4TMS,isomer #1COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C(N(C=O)[Si](C)(C)C)=C2)[Si](C)(C)C)C=C13382.4Standard polar33892256
Arformoterol,1TBDMS,isomer #1COC1=CC=C(C[C@@H](C)NC[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O)C(NC=O)=C2)C=C13498.6Semi standard non polar33892256
Arformoterol,1TBDMS,isomer #2COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(NC=O)=C2)C=C13530.2Semi standard non polar33892256
Arformoterol,1TBDMS,isomer #3COC1=CC=C(C[C@@H](C)N(C[C@H](O)C2=CC=C(O)C(NC=O)=C2)[Si](C)(C)C(C)(C)C)C=C13546.0Semi standard non polar33892256
Arformoterol,1TBDMS,isomer #4COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC=C(O)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)C=C13292.6Semi standard non polar33892256
Arformoterol,2TBDMS,isomer #1COC1=CC=C(C[C@@H](C)NC[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(NC=O)=C2)C=C13679.4Semi standard non polar33892256
Arformoterol,2TBDMS,isomer #2COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O)C(NC=O)=C2)[Si](C)(C)C(C)(C)C)C=C13753.9Semi standard non polar33892256
Arformoterol,2TBDMS,isomer #3COC1=CC=C(C[C@@H](C)NC[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)C=C13415.4Semi standard non polar33892256
Arformoterol,2TBDMS,isomer #4COC1=CC=C(C[C@@H](C)N(C[C@H](O)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(NC=O)=C2)[Si](C)(C)C(C)(C)C)C=C13773.3Semi standard non polar33892256
Arformoterol,2TBDMS,isomer #5COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)C=C13525.0Semi standard non polar33892256
Arformoterol,2TBDMS,isomer #6COC1=CC=C(C[C@@H](C)N(C[C@H](O)C2=CC=C(O)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)[Si](C)(C)C(C)(C)C)C=C13536.9Semi standard non polar33892256
Arformoterol,3TBDMS,isomer #1COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(NC=O)=C2)[Si](C)(C)C(C)(C)C)C=C13964.3Semi standard non polar33892256
Arformoterol,3TBDMS,isomer #1COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(NC=O)=C2)[Si](C)(C)C(C)(C)C)C=C13498.4Standard non polar33892256
Arformoterol,3TBDMS,isomer #1COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(NC=O)=C2)[Si](C)(C)C(C)(C)C)C=C13811.3Standard polar33892256
Arformoterol,3TBDMS,isomer #2COC1=CC=C(C[C@@H](C)NC[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)C=C13646.0Semi standard non polar33892256
Arformoterol,3TBDMS,isomer #2COC1=CC=C(C[C@@H](C)NC[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)C=C13155.3Standard non polar33892256
Arformoterol,3TBDMS,isomer #2COC1=CC=C(C[C@@H](C)NC[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)C=C13683.5Standard polar33892256
Arformoterol,3TBDMS,isomer #3COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)[Si](C)(C)C(C)(C)C)C=C13738.7Semi standard non polar33892256
Arformoterol,3TBDMS,isomer #3COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)[Si](C)(C)C(C)(C)C)C=C13331.6Standard non polar33892256
Arformoterol,3TBDMS,isomer #3COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)[Si](C)(C)C(C)(C)C)C=C13805.7Standard polar33892256
Arformoterol,3TBDMS,isomer #4COC1=CC=C(C[C@@H](C)N(C[C@H](O)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)[Si](C)(C)C(C)(C)C)C=C13783.2Semi standard non polar33892256
Arformoterol,3TBDMS,isomer #4COC1=CC=C(C[C@@H](C)N(C[C@H](O)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)[Si](C)(C)C(C)(C)C)C=C13343.3Standard non polar33892256
Arformoterol,3TBDMS,isomer #4COC1=CC=C(C[C@@H](C)N(C[C@H](O)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)[Si](C)(C)C(C)(C)C)C=C13862.2Standard polar33892256
Arformoterol,4TBDMS,isomer #1COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)[Si](C)(C)C(C)(C)C)C=C13976.1Semi standard non polar33892256
Arformoterol,4TBDMS,isomer #1COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)[Si](C)(C)C(C)(C)C)C=C13359.3Standard non polar33892256
Arformoterol,4TBDMS,isomer #1COC1=CC=C(C[C@@H](C)N(C[C@H](O[Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C(N(C=O)[Si](C)(C)C(C)(C)C)=C2)[Si](C)(C)C(C)(C)C)C=C13677.7Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Arformoterol GC-MS (Non-derivatized) - 70eV, Positivesplash10-00or-2902000000-10d83ebb89a446028d152017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Arformoterol GC-MS (2 TMS) - 70eV, Positivesplash10-0079-1290400000-a5f812e6f46ebe2c45732017-10-06Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Arformoterol GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Arformoterol 10V, Positive-QTOFsplash10-00mk-0119000000-960431f56a40133b85732016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Arformoterol 20V, Positive-QTOFsplash10-002b-0937000000-93717c858174f9fabf662016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Arformoterol 40V, Positive-QTOFsplash10-0002-0900000000-d7f4b9eb1c78823571732016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Arformoterol 10V, Negative-QTOFsplash10-004l-4209000000-f9910c5b8f497127e7ca2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Arformoterol 20V, Negative-QTOFsplash10-03fu-3619000000-7dd84dcd46e2292468392016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Arformoterol 40V, Negative-QTOFsplash10-002f-9400000000-58f5ee81bd6c210528d72016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Arformoterol 10V, Positive-QTOFsplash10-002b-0059000000-c0053d7ff48e5b7bf21e2021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Arformoterol 20V, Positive-QTOFsplash10-05bb-0797000000-ccdaa7ef72717418b1b72021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Arformoterol 40V, Positive-QTOFsplash10-022c-1911000000-a90ad156589941d202e72021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Arformoterol 10V, Negative-QTOFsplash10-0007-0039000000-690e9c11e66c66a1a0052021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Arformoterol 20V, Negative-QTOFsplash10-0007-3795000000-80c4a6628c8460481d112021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Arformoterol 40V, Negative-QTOFsplash10-0017-5391000000-9e5db81cdfc6dd49e8ea2021-10-11Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB01274 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB01274 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB01274
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID2340731
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkArformoterol
METLIN IDNot Available
PubChem Compound3083544
PDB IDNot Available
ChEBI ID408174
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Cazzola M, Matera MG, Lotvall J: Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2005 Jul;14(7):775-83. [PubMed:16022567 ]
  2. Kharidia J, Fogarty CM, Laforce CF, Maier G, Hsu R, Dunnington KM, Curry L, Baumgartner RA, Hanrahan JP: A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008 Aug;21(4):657-62. doi: 10.1016/j.pupt.2008.03.003. Epub 2008 Apr 7. [PubMed:18501650 ]
  3. Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP: Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Feb;29(2):261-78. [PubMed:17472819 ]
  4. Donohue JF, Hanania NA, Sciarappa KA, Goodwin E, Grogan DR, Baumgartner RA, Hanrahan JP: Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis. 2008 Apr;2(2):37-48. doi: 10.1177/1753465808089455. [PubMed:19124357 ]
  5. Panettieri RA Jr, MacIntyre N, Sims M, Kerwin E, Fogarty C, Noonan M, Claus R, Andrews WT: Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study. Clin Ther. 2009 Aug;31(8):1716-23. doi: 10.1016/j.clinthera.2009.08.012. [PubMed:19808130 ]
  6. Hanania NA, Donohue JF, Nelson H, Sciarappa K, Goodwin E, Baumgartner RA, Hanrahan JP: The safety and efficacy of arformoterol and formoterol in COPD. COPD. 2010 Feb;7(1):17-31. doi: 10.3109/15412550903499498. [PubMed:20214460 ]

Enzymes

General function:
Involved in monooxygenase activity
Specific function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan.
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular weight:
55627.365
References
  1. Somers GI, Lindsay N, Lowdon BM, Jones AE, Freathy C, Ho S, Woodrooffe AJ, Bayliss MK, Manchee GR: A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805. Epub 2007 Jul 12. [PubMed:17627976 ]
  2. Zhang M, Fawcett JP, Kennedy JM, Shaw JP: Stereoselective glucuronidation of formoterol by human liver microsomes. Br J Clin Pharmacol. 2000 Feb;49(2):152-7. [PubMed:10671910 ]
General function:
Involved in monooxygenase activity
Specific function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular weight:
55944.565
References
  1. Somers GI, Lindsay N, Lowdon BM, Jones AE, Freathy C, Ho S, Woodrooffe AJ, Bayliss MK, Manchee GR: A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805. Epub 2007 Jul 12. [PubMed:17627976 ]
  2. Zhang M, Fawcett JP, Kennedy JM, Shaw JP: Stereoselective glucuronidation of formoterol by human liver microsomes. Br J Clin Pharmacol. 2000 Feb;49(2):152-7. [PubMed:10671910 ]
General function:
Involved in monooxygenase activity
Specific function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular weight:
55768.94
References
  1. Somers GI, Lindsay N, Lowdon BM, Jones AE, Freathy C, Ho S, Woodrooffe AJ, Bayliss MK, Manchee GR: A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805. Epub 2007 Jul 12. [PubMed:17627976 ]
  2. Zhang M, Fawcett JP, Kennedy JM, Shaw JP: Stereoselective glucuronidation of formoterol by human liver microsomes. Br J Clin Pharmacol. 2000 Feb;49(2):152-7. [PubMed:10671910 ]
General function:
Involved in monooxygenase activity
Specific function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular weight:
56517.005
References
  1. Somers GI, Lindsay N, Lowdon BM, Jones AE, Freathy C, Ho S, Woodrooffe AJ, Bayliss MK, Manchee GR: A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805. Epub 2007 Jul 12. [PubMed:17627976 ]
  2. Zhang M, Fawcett JP, Kennedy JM, Shaw JP: Stereoselective glucuronidation of formoterol by human liver microsomes. Br J Clin Pharmacol. 2000 Feb;49(2):152-7. [PubMed:10671910 ]
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
Beta-adrenergic receptors mediate the catecholamine- induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular weight:
46458.3
References
  1. Authors unspecified: Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol. Drugs R D. 2004;5(1):25-7. [PubMed:14725487 ]
  2. Op't Holt TB: Inhaled beta agonists. Respir Care. 2007 Jul;52(7):820-32. [PubMed:17594727 ]
  3. Matera MG, Cazzola M: ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs. 2007;67(4):503-15. [PubMed:17352511 ]
  4. Cazzola M, Hanania NA, Matera MG: Arformoterol tartrate in the treatment of COPD. Expert Rev Respir Med. 2010 Apr;4(2):155-62. doi: 10.1586/ers.10.16. [PubMed:20406080 ]
  5. Cazzola M, Matera MG, Lotvall J: Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2005 Jul;14(7):775-83. [PubMed:16022567 ]
  6. Kharidia J, Fogarty CM, Laforce CF, Maier G, Hsu R, Dunnington KM, Curry L, Baumgartner RA, Hanrahan JP: A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008 Aug;21(4):657-62. doi: 10.1016/j.pupt.2008.03.003. Epub 2008 Apr 7. [PubMed:18501650 ]
  7. Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP: Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Feb;29(2):261-78. [PubMed:17472819 ]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]